These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 15212157)
41. Design for optimized topical delivery: Prodrugs and a paradigm change. Sloan KB; Wasdo SC; Rautio J Pharm Res; 2006 Dec; 23(12):2729-47. PubMed ID: 17109215 [TBL] [Abstract][Full Text] [Related]
42. Effect of permeation enhancers on transdermal delivery of fluoxetine: in vitro and in vivo evaluation. Jung E; Kang YP; Yoon IS; Kim JS; Kwon SW; Chung SJ; Shim CK; Kim DD Int J Pharm; 2013 Nov; 456(2):362-9. PubMed ID: 24012861 [TBL] [Abstract][Full Text] [Related]
43. Design, synthesis and characterization of captopril prodrugs for enhanced percutaneous absorption. Moss GP; Gullick DR; Cox PA; Alexander C; Ingram MJ; Smart JD; Pugh WJ J Pharm Pharmacol; 2006 Feb; 58(2):167-77. PubMed ID: 16451744 [TBL] [Abstract][Full Text] [Related]
44. Transdermal delivery of 5-fluorouracil through skin of hairless mice and humans in vitro: a comparison of the effect of formulations and a prodrug. Sherertz EF; Sloan KB; McTiernan RG Arch Dermatol Res; 1990; 282(7):463-8. PubMed ID: 2078050 [TBL] [Abstract][Full Text] [Related]
45. Enhanced delivery of zidovudine through rat and human skin via ester prodrugs. Seki T; Kawaguchi T; Juni K Pharm Res; 1990 Sep; 7(9):948-52. PubMed ID: 2235895 [TBL] [Abstract][Full Text] [Related]
46. Ketorolac amide prodrugs for transdermal delivery: stability and in vitro rat skin permeation studies. Kim BY; Doh HJ; Le TN; Cho WJ; Yong CS; Choi HG; Kim JS; Lee CH; Kim DD Int J Pharm; 2005 Apr; 293(1-2):193-202. PubMed ID: 15778057 [TBL] [Abstract][Full Text] [Related]
47. Synthesis, in vitro evaluation, and antileishmanial activity of water-soluble prodrugs of buparvaquone. Mäntylä A; Garnier T; Rautio J; Nevalainen T; Vepsälainen J; Koskinen A; Croft SL; Järvinen T J Med Chem; 2004 Jan; 47(1):188-95. PubMed ID: 14695832 [TBL] [Abstract][Full Text] [Related]
48. Effect of vehicles on the maximum transepidermal flux of similar size phenolic compounds. Zhang Q; Li P; Liu D; Roberts MS Pharm Res; 2013 Jan; 30(1):32-40. PubMed ID: 22923350 [TBL] [Abstract][Full Text] [Related]
49. Evaluation of stereoselective transdermal transport and concurrent cutaneous hydrolysis of several ester prodrugs of propranolol: mechanism of stereoselective permeation. Ahmed S; Imai T; Otagiri M Pharm Res; 1996 Oct; 13(10):1524-9. PubMed ID: 8899845 [TBL] [Abstract][Full Text] [Related]
50. Combined effects of iontophoretic and chemical enhancement on drug delivery. II. Transport across human and murine skin. Nolan LM; Corish J; Corrigan OI; Fitzpatrick D Int J Pharm; 2007 Aug; 341(1-2):114-24. PubMed ID: 17502130 [TBL] [Abstract][Full Text] [Related]
51. Transdermal delivery of zidovudine (AZT): the effects of vehicles, enhancers, and polymer membranes on permeation across cadaver pig skin. Suwanpidokkul N; Thongnopnua P; Umprayn K AAPS PharmSciTech; 2004 Aug; 5(3):e48. PubMed ID: 15760081 [TBL] [Abstract][Full Text] [Related]
52. Synergistic effect of isopropyl myristate and glyceryl monocaprylate on the skin permeation of pentazocine. Furuishi T; Fukami T; Suzuki T; Takayama K; Tomono K Biol Pharm Bull; 2010; 33(2):294-300. PubMed ID: 20118556 [TBL] [Abstract][Full Text] [Related]
53. Piperazinylalkyl prodrugs of naproxen improve in vitro skin permeation. Rautio J; Nevalainen T; Taipale H; Vepsäläinen J; Gynther J; Laine K; Järvinen T Eur J Pharm Sci; 2000 Aug; 11(2):157-63. PubMed ID: 10915963 [TBL] [Abstract][Full Text] [Related]
54. A Data-Mining Approach for the Quantitative Assessment of Physicochemical Properties of Molecular Compounds in the Skin Flux. Choi HK; Acharya G; Lee Y; Lee CH AAPS PharmSciTech; 2021 Mar; 22(3):117. PubMed ID: 33768360 [TBL] [Abstract][Full Text] [Related]
55. Preparation and characterization of microemulsion formulations of nicotinic acid and its prodrugs for transdermal delivery. Tashtoush BM; Bennamani AN; Al-Taani BM Pharm Dev Technol; 2013; 18(4):834-43. PubMed ID: 23030413 [TBL] [Abstract][Full Text] [Related]
56. Percutaneous delivery of thalidomide and its N-alkyl analogs. Goosen C; Laing TJ; du Plessis J; Goosen TC; Lu GW; Flynn GL Pharm Res; 2002 Apr; 19(4):434-9. PubMed ID: 12033376 [TBL] [Abstract][Full Text] [Related]
57. Application of the transformed Potts-Guy equation to in vivo human skin data. Roberts WJ; Sloan KB J Pharm Sci; 2001 Sep; 90(9):1318-23. PubMed ID: 11745784 [TBL] [Abstract][Full Text] [Related]
58. Effect of vehicles and penetration enhancers on the in vitro and in vivo percutaneous absorption of methotrexate and edatrexate through hairless mouse skin. Chatterjee DJ; Li WY; Koda RT Pharm Res; 1997 Aug; 14(8):1058-65. PubMed ID: 9279889 [TBL] [Abstract][Full Text] [Related]
59. Enhancement of transdermal apomorphine delivery with a diester prodrug strategy. Liu KS; Sung KC; Al-Suwayeh SA; Ku MC; Chu CC; Wang JJ; Fang JY Eur J Pharm Biopharm; 2011 Aug; 78(3):422-31. PubMed ID: 21315820 [TBL] [Abstract][Full Text] [Related]
60. Cyclization-activated prodrugs: N-(substituted 2-hydroxyphenyl and 2-hydroxypropyl)carbamates based on ring-opened derivatives of active benzoxazolones and oxazolidinones as mutual prodrugs of acetaminophen. Vigroux A; Bergon M; Zedde C J Med Chem; 1995 Sep; 38(20):3983-94. PubMed ID: 7562932 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]